Abingdon Health Plc
ABDXF
Other OTC0.17
USD
-0.03
- -
Abingdon Health Plc
ABDXF
(Other OTC)
Recent
price
0.17
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Abingdon Health Plc develops, manufactures and sells lateral flow diagnostic tests and provides contract development and manufacturing organization (CDMO) services, regulatory consultancy, analytical services and commercial support to clients in healthcare, animal health, plant health, infectious disease monitoring and companion diagnostics sectors; core offerings include professional-use and self-tests such as AbC-19 rapid antigen tests for COVID-19, Simply Test self-testing kits, Pocket Diagnostic nucleic acid lateral flow immunoassays (NALFIA), plant health tests for in-field disease detection, research antibodies and companion diagnostics like Seralite-FLC for multiple myeloma biomarkers, alongside full-service lateral flow solutions encompassing assay development from proof-of-concept through scale-up, technical transfer, strip and card manufacturing, device assembly, kitting, packaging, stability studies, clinical trial design and go-to-market strategies. The company operates internationally from headquarters at York Biotech Campus, Sand Hutton, York, England, with additional facilities in Doncaster, UK and Madison, Wisconsin, USA, targeting customers including pharmaceutical firms, biotech companies, research institutions and distributors across the UK, USA, Canada, Europe and rest of world. Founded in 2008, Abingdon Health Plc expanded its integrated CDMO capabilities through the August 2024 acquisition of regulatory services provider CS Lifesciences for up to £3.2 million in cash and shares; opened Abingdon Analytical Ltd laboratory in Doncaster in December 2024 and a US CDMO site in Madison fully operational by April 2025; secured major contracts including a US$2 million sexually transmitted disease test development deal, €2 million companion diagnostic project with a European biotech, US$2.5 million global pharmaceutical companion diagnostic, and a post-period c.US$2 million semi-quantitative multiplex lateral flow system; formed strategic partnership with Okos Diagnostics for avian flu (H5N1) kits and SymbioTex for seaweed-based eco-friendly housings; received £800,000 UK Research and Innovation funding for malaria point-of-care tests; and completed fundraises of £5.2 million net in August 2024 and £3.2 million net in October 2025 to support US expansion and larger projects.
Abingdon Health plc to Present at the Small Cap Growth Virtual Investor Conference June 4th
Abingdon Health shares to begin trading on US OTCQB market from 21 April